Original ArticleMulti-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds

Add time:09/28/2019    Source:sciencedirect.com

Oncolytic viruses (OV) are an emerging class of anticancer bio-therapeutics that induce antitumor immunity through selective replication in tumor cells. However, the efficacy of OVs as single agents remains limited. We introduce a strategy that boosts the therapeutic efficacy of OVs by combining their activity with immuno-modulating, small molecule protein tyrosine phosphatase inhibitors. We report that vanadium-based phosphatase inhibitors enhance OV infection in vitro and ex vivo, in resistant tumor cell lines. Furthermore, vanadium compounds increase antitumor efficacy in combination with OV in several syngeneic tumor models, leading to systemic and durable responses, even in models otherwise refractory to OV and drug alone. Mechanistically, this involves subverting the antiviral type I IFN response toward a death-inducing and pro-inflammatory type II IFN response, leading to improved OV spread, increased bystander killing of cancer cells, and enhanced antitumor immune stimulation. Overall, we showcase a new ability of vanadium compounds to simultaneously maximize viral oncolysis and systemic anticancer immunity, offering new avenues for the development of improved immunotherapy strategies.

We also recommend Trading Suppliers and Manufacturers of VANADIUM(V) OXYTRIETHOXIDE (cas 1686-22-2). Pls Click Website Link as below: cas 1686-22-2 suppliers

Prev:Five- and six-coordinate vanadium(V) complexes with tridentate Schiff base ligands derived from S(+)-isoleucinol: Synthesis, characterization and catalytic activity in the oxidation of sulfides and olefins
Next:Enhancement of Seebeck coefficient of mesoporous SrTiO3 with V-group elements V, Nb, and Ta substituted for Ti)